1. Home
  2. AKTX vs NDLS Comparison

AKTX vs NDLS Comparison

Compare AKTX & NDLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKTX
  • NDLS
  • Stock Information
  • Founded
  • AKTX N/A
  • NDLS 1995
  • Country
  • AKTX United States
  • NDLS United States
  • Employees
  • AKTX N/A
  • NDLS N/A
  • Industry
  • AKTX Biotechnology: Pharmaceutical Preparations
  • NDLS Restaurants
  • Sector
  • AKTX Health Care
  • NDLS Consumer Discretionary
  • Exchange
  • AKTX Nasdaq
  • NDLS Nasdaq
  • Market Cap
  • AKTX 35.7M
  • NDLS 32.9M
  • IPO Year
  • AKTX N/A
  • NDLS 2013
  • Fundamental
  • Price
  • AKTX $1.10
  • NDLS $0.89
  • Analyst Decision
  • AKTX
  • NDLS Strong Buy
  • Analyst Count
  • AKTX 0
  • NDLS 2
  • Target Price
  • AKTX N/A
  • NDLS $3.00
  • AVG Volume (30 Days)
  • AKTX 25.6K
  • NDLS 224.0K
  • Earning Date
  • AKTX 08-18-2025
  • NDLS 08-06-2025
  • Dividend Yield
  • AKTX N/A
  • NDLS N/A
  • EPS Growth
  • AKTX N/A
  • NDLS N/A
  • EPS
  • AKTX N/A
  • NDLS N/A
  • Revenue
  • AKTX N/A
  • NDLS $495,670,000.00
  • Revenue This Year
  • AKTX N/A
  • NDLS $5.37
  • Revenue Next Year
  • AKTX N/A
  • NDLS $0.68
  • P/E Ratio
  • AKTX N/A
  • NDLS N/A
  • Revenue Growth
  • AKTX N/A
  • NDLS N/A
  • 52 Week Low
  • AKTX $0.85
  • NDLS $0.55
  • 52 Week High
  • AKTX $4.40
  • NDLS $1.83
  • Technical
  • Relative Strength Index (RSI)
  • AKTX 39.44
  • NDLS 63.57
  • Support Level
  • AKTX $1.10
  • NDLS $0.66
  • Resistance Level
  • AKTX $1.15
  • NDLS $0.82
  • Average True Range (ATR)
  • AKTX 0.04
  • NDLS 0.09
  • MACD
  • AKTX 0.00
  • NDLS 0.03
  • Stochastic Oscillator
  • AKTX 0.00
  • NDLS 99.97

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.

About NDLS Noodles & Company

Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services.

Share on Social Networks: